GSK adoptive cell therapy for Tumors

GSK Investigational Site, Richmond, VA
TumorsGSK adoptive cell therapy - Biological
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will evaluate the long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy.

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 15 years

15 years
Number of deaths
Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples
Hepatitis Viruses
Number of participants with integrated vector sequences and vector integration patterns identified in peripheral blood samples
Time to death
Year 15
Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Participants receiving GSK adoptive cell therapy
1 of 1

Experimental Treatment

250 Total Participants · 1 Treatment Group

Primary Treatment: GSK adoptive cell therapy · No Placebo Group · Phase 1

Participants receiving GSK adoptive cell therapy
Experimental Group · 1 Intervention: GSK adoptive cell therapy · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 15 years

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,672 Previous Clinical Trials
7,956,821 Total Patients Enrolled
4 Trials studying Tumors
369 Patients Enrolled for Tumors
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,573 Previous Clinical Trials
6,137,043 Total Patients Enrolled
1 Trials studying Tumors
12 Patients Enrolled for Tumors

Eligibility Criteria

Age Any Age · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has GSK's adoptive cell therapy attained regulatory clearance?

"This early-stage trial has minimal safety or efficacy data available, so GSK's adoptive cell therapy was assigned a score of 1." - Anonymous Online Contributor

Unverified Answer

Is this research endeavor open to new participants?

"Data hosted on shows that this medical trial is now welcoming participants. This experiment was first put online on April 9th 2018, and has been modified as recently as November 21st 2022." - Anonymous Online Contributor

Unverified Answer

What is the current cohort size of this experiment?

"Affirmative.'s records show that this clinical trial, initially posted on 4/9/2018, is actively enrolling subjects with up to 250 participants being admitted at 31 different sites." - Anonymous Online Contributor

Unverified Answer

How extensively is this trial being conducted throughout the medical field?

"This clinical trial is being conducted across 31 medical centres, including New Haven, Philadelphia and Salt Lake City. To reduce any potential travel burden on participants it's recommended to choose the centre nearest you." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.